Pallas Capital Advisors LLC Takes $920,000 Position in Becton, Dickinson and Company $BDX

Pallas Capital Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 6,076 shares of the medical instruments supplier’s stock, valued at approximately $920,000.

Several other institutional investors have also recently added to or reduced their stakes in BDX. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth about $25,000. SHP Wealth Management acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $26,000. Meeder Asset Management Inc. raised its position in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 102 shares during the last quarter. Main Street Group LTD purchased a new position in shares of Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Finally, Bell Investment Advisors Inc acquired a new stake in Becton, Dickinson and Company during the second quarter worth approximately $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.5%

Shares of BDX opened at $181.17 on Wednesday. The firm has a market cap of $49.92 billion, a PE ratio of 54.57, a price-to-earnings-growth ratio of 12.93 and a beta of 0.19. The company’s fifty day moving average is $159.06 and its two-hundred day moving average is $161.12. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the firm posted $3.68 EPS. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BDX shares. Piper Sandler boosted their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research report on Monday, July 6th. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Weiss Ratings reissued a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Finally, Bank of America lowered their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $185.67.

Insider Activity

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 11,779 shares of company stock valued at $1,974,669 in the last three months. Corporate insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.